九典制藥(300705.SZ):洛索洛芬鈉凝膠貼膏2022年成功開發目標連鎖100多家,今年計劃開發排名前200的連鎖藥房
格隆匯6月7日丨九典制藥(300705.SZ)近日接受高毅資產、易方達基金等等機構調研,問答環節中,就“公司洛索洛芬鈉凝膠貼膏在連鎖端的推廣情況怎麼樣?”,公司回覆稱,洛索洛芬鈉凝膠貼膏這個產品從2022年正式開始連鎖端的推廣,2022年成功開發目標連鎖100多家,覆蓋門店近2萬家,今年計劃開發排名前200的連鎖藥房。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.